Annette North is CLO & VP at Turning Point Therapeutics, Inc. (TPTX). They have made 5 open-market trades across 1 company since 2021, most recently 2022-02-09.
CIK 0001341011
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TPTX | 11,696 | $889K |
Shares reported on the most recent Form 4, priced at the 2022-02-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TPTX | SELL | 2022-02-09 | 2022-02-11 | $36.30 | $24K | -8.3% | -28.0% | -14.6% |
| TPTX | SELL | 2021-08-30 | 2021-08-31 | $80.00 | $800K | +3.2% | -13.5% | -50.1% |
| TPTX | SELL | 2021-06-15 | 2021-06-16 | $77.00 | $2.1M | -2.3% | -14.0% | -1.3% |
| TPTX | SELL | 2021-03-08 | 2021-03-09 | $109.85 | $4.3M | -8.0% | -28.6% | -36.9% |
| TPTX | SELL | 2021-02-01 | 2021-02-02 | $125.61 | $5.7M | +1.9% | -21.4% | -41.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.